DRUG vs. PTPI, CPHI, LIPO, KZIA, ZVSA, SEEL, NEXI, GTBP, THAR, and XCUR
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Petros Pharmaceuticals (PTPI), China Pharma (CPHI), Lipella Pharmaceuticals (LIPO), Kazia Therapeutics (KZIA), ZyVersa Therapeutics (ZVSA), Seelos Therapeutics (SEEL), NexImmune (NEXI), GT Biopharma (GTBP), Tharimmune (THAR), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry.
Petros Pharmaceuticals (NASDAQ:PTPI) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
Petros Pharmaceuticals received 1 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
In the previous week, Petros Pharmaceuticals had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Petros Pharmaceuticals and 2 mentions for Bright Minds Biosciences. Petros Pharmaceuticals' average media sentiment score of 1.61 beat Bright Minds Biosciences' score of -0.27 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.
Petros Pharmaceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Petros Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 629.79%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Petros Pharmaceuticals is more favorable than Bright Minds Biosciences.
Bright Minds Biosciences has a net margin of 0.00% compared to Bright Minds Biosciences' net margin of -181.87%. Bright Minds Biosciences' return on equity of -68.90% beat Petros Pharmaceuticals' return on equity.
12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 36.4% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bright Minds Biosciences has lower revenue, but higher earnings than Petros Pharmaceuticals. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Petros Pharmaceuticals beats Bright Minds Biosciences on 9 of the 15 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
